Most of what is written about pharmacy valuation assumes a community pharmacy with steady prescription volume and normal margins. Compounding pharmacies break that model in two directions. The good ones earn margins that retail pharmacies cannot match. The young or small ones often lose money, sometimes for years, while carrying an expensive, specialized facility that a buyer cannot easily replace.
That means a compounding pharmacy for sale is valued in one of two quite different ways, depending on what its earnings look like. This article explains both, drawing on compounding pharmacies we have valued and marketed, and covers the factors that move the number in either direction. The examples are illustrative: figures are rounded or given as ranges, and details from more than one file are combined, so no single pharmacy can be identified.
For the general method, see our guide to pharmacy valuation in Canada. This article covers what is different about compounding.
Path one: the compounding pharmacy that makes money
If a compounding pharmacy has three years of stable or growing earnings and a reasonably diversified prescriber base, it is valued like any other pharmacy. Start with normalized EBITDA: reported earnings adjusted for the owner’s actual role, a market wage for the pharmacist manager, related party rent at market, and one time costs. Our article on EBITDA normalization covers the method. Apply a multiple, usually 4 to 6 times for Canadian community pharmacies, and add inventory at cost.
There is no special compounding multiple. What compounding changes is where in the range a pharmacy lands and how much of the price is paid at closing.
Factors that push a compounding pharmacy toward the top of the range or above it:
- Sterile capacity that is certified and in use. Sterile suites are expensive, slow to build and scarce. A buyer who needs sterile capability values the 12 to 18 months it saves.
- A diversified prescriber base. Dozens of active prescribers across several specialties, with none above 15 or 20 percent.
- Recurring B2B work from other pharmacies under written agreements.
- A documented quality system: SOPs, formula records, certifications, training records and inspection reports that a buyer can step into.
- A healthy cash share, revenue that does not depend on any formulary.
Factors that push it down:
- Prescriber concentration. One prescriber, often the owner or an adjoining clinic, writing a large share of the work.
- Formula concentration. One or two preparations carrying the business.
- Earnings from a recent price change that has not yet been tested by a full year of customer response.
- Revenue at regulatory risk, for example compounded GLP 1 products.
- Key person risk. A single compounding pharmacist who holds the formulas and relationships.
Path two: when the multiple gives you nothing
Many compounding pharmacies do not have three years of stable profit. They are young, or small, or carrying the cost of a facility built for more volume than they have yet. Apply a multiple to negative EBITDA and the answer is zero. That answer is wrong, and buyers know it, because nobody would hand over a licensed, inspected compounding pharmacy for nothing.
In that case the value is rebuilt from what a buyer actually gets, and checked against what it would cost them to get it another way.
Take a typical case: a small, established non sterile specialty compounder whose statements show a loss in most years, even though its compound volume is steady and its margins are reasonable. There are no earnings to multiply, so the value is built up in layers:
| Layer | How it is measured |
|---|---|
| Compounding equipment | Priced item by item at fair value in use, not at what it cost new |
| Other equipment: safe, fridge, computers, carts | A reasonable allowance, since these are rarely priced individually |
| Leasehold improvements | Net book value, adjusted if the lease term left is short |
| Dispensary fixtures, IT and phone | Fair value in use |
| Tangible assets in place | Sum of the above |
| Inventory | At cost, counted at closing |
| Turnkey readiness credit | A specific, itemized allowance for what is already working, well below the cost of building it again |
| Indicated value | Assets plus inventory plus the readiness credit |
The turnkey readiness credit is the part buyers argue about, so it has to be specific. It usually covers the pharmacy licence and a clean inspection history, an SOP and quality system aligned with NAPRA standards and in daily use, certified containment and calibrated balances, configured dispensing and compounding software, wholesaler and compounding supplier accounts, an operating website and phone line, ordering forms for any pharmacies that buy compounds, and a trained compounding pharmacist willing to stay.
Two reference points frame the range. At the low end is what the equipment would bring at liquidation, usually a small fraction of its book value, which is where a buyer who wants to push will start. At the high end is what it would cost to build the same pharmacy new: construction, equipment, soft costs, several hundred hours of set up work, carrying costs and opening stock, plus six to nine months to open and a year or two of losses while it ramps. For even a small non sterile compounder, that build cost is commonly well into six figures, so a buyer who pays a fair asset based price saves money and, more importantly, saves time. Our article on what it costs to build a compounding pharmacy breaks that cost down.
No goodwill is claimed on historical earnings when there are none to claim. Strategic value to a particular buyer, such as moving their own outsourced compounding in house or adding a sterile suite in available space, is better left as a negotiation point than built into the asking price.
The young compounding pharmacy: replacement cost versus earnings
The opposite problem shows up in a young compounding led pharmacy with a sterile suite. A facility like that can easily cost more than half a million dollars to build, and in its first year it may produce revenue of a similar order and gross profit of perhaps half that, while still growing.
The owner’s view of value started from what they had spent. A buyer’s view starts from what the business earns and will earn. Those two numbers are far apart in a young compounding pharmacy, and neither one alone is the answer.
What a buyer will pay is usually:
- earnings value on a normalized basis, often using a forward year if growth is clear and documented, with some of the price deferred until that growth shows up; plus
- a share of the replacement cost and time saved, because building the same sterile facility would take 12 to 18 months and several hundred thousand dollars, and the buyer avoids the first year of ramp up.
Build cost is a ceiling on what a buyer pays for assets, not a floor. And it only counts if it is documented. Owners often quote a build figure well above what their invoices support. A complete build file, with contracts, final accounts, invoices, who paid each one and a fixed asset register, is worth real money in a sale. Our article on what it costs to build a compounding pharmacy shows what a full file looks like.
Valuing a compounding business before it has revenue
For a planned or very early stage compounding business, such as a centralized facility that will compound for other pharmacies, there are no earnings or operating history to value. Investors and partners use forward looking methods instead, and usually blend more than one:
Comparable transactions, discounted. Take the EBITDA the plan projects in a near year, apply a multiple, and discount back for time and risk. For example, a plan projecting $750,000 of EBITDA in year two, at 7 times, is worth $5.25 million in year two money. Discounted two years at 35 percent, that is about $2.9 million today.
Venture method. Pick an exit year and multiple, then discount at the return an investor in a start up would demand, often 30 to 45 percent.
Discounted cash flow at a high discount rate that reflects the risk of a business with no history.
These numbers are only as good as the plan behind them, and lenders and partners will test the volume assumptions hard. But they give owners and partners a defensible basis for setting equity splits or valuing in kind contributions.
What buyers ask for on a compounding file
In our experience, these are the questions that come first:
Prescriber split. What share of dollars comes from the top prescriber, the top five and everyone else, and how that has changed over three years. If the owner or an adjoining clinic writes a large share, buyers will ask for a transition agreement and may propose an earn out tied to retention.
Formula split. The top twenty formulas by revenue and gross profit, and the share of the top one and top five.
Compound versus commercial. Separate margin and revenue for each, because blended numbers hide the trend.
Fee schedule history. When prices last changed, by how much, and how customers and insurers responded.
Payer mix. Cash, private insurers and public plans, with write downs.
Quality and compliance. Current hood and cleanroom certifications, environmental monitoring records, the latest college inspection report, the SOP set and training records.
B2B contracts. Which pharmacies order, how much, under what written terms, and whether those agreements survive a change of owner.
Regulatory exposure. Any revenue from preparations that regulators have restricted or are reviewing.
Two counts of the same thing. Dispensing systems often report prescription counts and compound totals differently in different reports. Reconcile them before a buyer finds the difference.
The compounding pharmacist. Who holds the formulas, the skill and the prescriber relationships, and whether they will stay. Some buyers offer that person equity to keep them.
Deal structure fills the gap
Because compounding pharmacies carry concentration and key person risk, the gap between what a seller wants and what a buyer will pay at closing is often closed with structure rather than price alone. We have seen cash at closing plus a seller note; an earn out tied to retention of a key prescriber group, measured against a fixed baseline; a share of profit for a set number of years; equity for the compounding pharmacist with vesting; and inventory paid for separately at closing.
Each tool has limits. A seller who is also a prescriber should be careful about any payment that depends on prescription volume, because prescribing has to remain a matter of clinical judgment and patient choice. A seller note that is subordinated to the buyer’s own shareholder loans and deferred for a year is closer to unsecured equity than to a loan. Get advice before agreeing to either.
Licensing affects timing too. In most provinces the pharmacy licence does not transfer with the business. The buyer applies for its own licence and appoints a pharmacy manager, and that approval needs to be in the closing timeline.
How we help
We are pharmacists who have built, operated and sold our own pharmacies, and we have valued and marketed compounding pharmacies, from small non sterile specialty compounders to sterile start ups and planned B2B facilities. For owners we prepare valuations that a buyer and a lender will accept. For buyers we test whether a compounding pharmacy for sale is worth more than building one. For founders we help decide whether to build at all.
To discuss a valuation, a purchase, or planning a new compounding pharmacy, request a valuation, see our guide to building a pharmacy in Canada, or contact us to book a consultation.